Cullinan Oncology Llc Stock Fundamentals
| CGEM Stock | USD 12.54 0.32 2.62% |
Cullinan Oncology LLC fundamentals help investors to digest information that contributes to Cullinan Oncology's financial success or failures. It also enables traders to predict the movement of Cullinan Stock. The fundamental analysis module provides a way to measure Cullinan Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cullinan Oncology stock.
At this time, Cullinan Oncology's Research Development is very stable compared to the past year. As of the 25th of November 2024, Net Interest Income is likely to grow to about 22.7 M, though Operating Income is likely to grow to (181.5 M). Cullinan | Select Account or Indicator |
Cullinan Oncology LLC Company Shares Outstanding Analysis
Cullinan Oncology's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cullinan Oncology Shares Outstanding | 58.23 M |
Most of Cullinan Oncology's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cullinan Oncology LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cullinan Shares Outstanding Historical Pattern
Today, most investors in Cullinan Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cullinan Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cullinan Oncology shares outstanding as a starting point in their analysis.
Cullinan Oncology Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Cullinan Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Cullinan Oncology LLC has 58.23 M of shares currently outstending. This is 67.75% lower than that of the Biotechnology sector and 45.51% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 89.82% higher than that of the company.
Cullinan Oncology LLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cullinan Oncology's current stock value. Our valuation model uses many indicators to compare Cullinan Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cullinan Oncology competition to find correlations between indicators driving Cullinan Oncology's intrinsic value. More Info.Cullinan Oncology LLC is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . At this time, Cullinan Oncology's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cullinan Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cullinan Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cullinan Oncology's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cullinan Oncology could also be used in its relative valuation, which is a method of valuing Cullinan Oncology by comparing valuation metrics of similar companies.Cullinan Oncology is currently under evaluation in shares outstanding category among its peers.
Cullinan Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cullinan Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cullinan Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Cullinan Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 154.54 M | ||||
| Shares Outstanding | 58.23 M | ||||
| Shares Owned By Insiders | 4.49 % | ||||
| Shares Owned By Institutions | 95.51 % | ||||
| Number Of Shares Shorted | 9.02 M | ||||
| Price To Earning | 5.23 X | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 26.88 X | ||||
| Gross Profit | 18.94 M | ||||
| EBITDA | (190.34 M) | ||||
| Net Income | (153.16 M) | ||||
| Cash And Equivalents | 611 M | ||||
| Cash Per Share | 13.40 X | ||||
| Total Debt | 3.59 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.04 X | ||||
| Book Value Per Share | 10.80 X | ||||
| Cash Flow From Operations | (134.28 M) | ||||
| Short Ratio | 24.87 X | ||||
| Earnings Per Share | (2.84) X | ||||
| Target Price | 33.0 | ||||
| Number Of Employees | 85 | ||||
| Beta | -0.12 | ||||
| Market Capitalization | 730.17 M | ||||
| Total Asset | 484.18 M | ||||
| Retained Earnings | (200.86 M) | ||||
| Working Capital | 452.05 M | ||||
| Net Asset | 484.18 M |
About Cullinan Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cullinan Oncology LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cullinan Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cullinan Oncology LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 310 K | 325.5 K | |
| Stock Based Compensation To Revenue | 1.16 | 1.03 | |
| Sales General And Administrative To Revenue | 1.38 | 1.23 | |
| Research And Ddevelopement To Revenue | 2.74 | 2.44 | |
| Capex To Revenue | 0.03 | 0.02 | |
| Revenue Per Share | 0.38 | 0.34 | |
| Ebit Per Revenue | (3.23) | (3.39) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Cullinan Oncology Piotroski F Score and Cullinan Oncology Altman Z Score analysis. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.